Business Context and Reporting Period
Company: Kewaunee Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended January 31, 2001
Business Overview: The Company manufactures laboratory and technical products. Operations are divided into Laboratory Products and Technical Products segments.
Key Financial Metrics
| Metric ($ in thousands) | 3 Months Ended Jan 31, 2001 | 9 Months Ended Jan 31, 2001 |
|---|---|---|
| Net Sales | $17,632 | $58,418 |
| Gross Profit | $3,005 | $10,999 |
| Gross Margin | 17.0% | 18.8% |
| Operating Earnings | $82 | $1,777 |
| Net Earnings (Loss) | ($198) | $798 |
| Diluted EPS | ($0.08) | $0.32 |
| Cash from Operations | N/A | $2,399 |
| Working Capital | $11,852 | N/A |
| Short-term Borrowings | $2,142 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.1% for the quarter and 3.3% for the nine-month period compared to the prior year, driven by strong demand for technical products offset by lower laboratory product sales.
- Margin Compression: Gross profit margins declined significantly from 24.7% to 17.0% (quarter) and 23.3% to 18.8% (nine months). Causes include lower selling prices, an unfavorable product mix (shift to lower-margin educational projects), and increased healthcare costs.
- Profitability Decline: Operating earnings dropped from $1.1 million to $82,000 for the quarter and from $3.6 million to $1.8 million for the nine-month period.
- Unusual Item: A $391,000 charge was recorded in "Other income (expense)" related to an arbitrator's decision on a construction dispute from 1990. Excluding this charge, the quarter would have shown a net profit of $52,000.
- Interest Expense: Increased due to higher debt levels under the revolving credit facility.
Outlook, Risks, and Management Commentary
- Liquidity: Working capital increased to $11.9 million. The current ratio improved to 2.23-to-1. The Company extended its unsecured revolving credit facility for two years, increasing the limit to $6 million.
- Capital Expenditures: Spending decreased to $1.5 million for the nine months ended Jan 31, 2001, compared to $2.7 million in the prior year.
- Risks: Management cites economic, competitive, and technological factors as risks. Specific market pressures include weakness in the industrial research market and price pressure in the educational laboratory market.
- Forward-Looking Statements: The filing includes a Safe Harbor statement noting that actual results may differ materially from expectations due to various uncertainties.
Investor Verification Checklist
- Verify the sustainability of the 7.7% decline in gross margins and the specific impact of healthcare cost increases.
- Confirm the status of the $391,000 construction dispute charge and whether further legal contingencies exist.
- Assess the trend in the "Technical Products" segment, which is currently offsetting declines in the core "Laboratory Products" segment.
- Review the utilization of the expanded $6 million credit facility and the impact of rising interest expenses on future profitability.
- Monitor the shift in product mix between high-margin industrial research projects and lower-margin educational projects.